FDA 483 - Zhaoke Pharmaceutical (Hefei) Company Limited - June 18, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Zhaoke Pharmaceutical (Hefei) Company Limited, a sterile drug manufacturer in Hefei, China, revealed significant deficiencies across its operations. Observations included incomplete laboratory records for microbial counts, inadequate laboratory controls for endotoxin and filter integrity, and insufficient validation of aseptic and sterilization processes. The firm also failed to establish and follow proper aseptic procedures, maintain equipment, and ensure data integrity with audit trails.
ID · 9b01a5d7-d702-4c4e-8e30-d4f16a37a509